EKF Diagnostics previews new connectivity solution for A1c POC analyzers at Medica 2016

EKF Diagnostics is previewing a new point-of-care (POC) connectivity solution for its range of HbA1c analyzers at Medica 2016 in Düsseldorf from November 14 to 17.

In Hall 3 / C70, EKF will showcase the new connectivity package for Quo-Test® and Quo-Lab® HbA1c analyzers. This package enables secure bidirectional communication between these POC analyzers and many central data management systems. Using the industry-recognized POCT1-A2 communication protocol, EKF’s connectivity solution unlocks new features to improve security and quality control (QC) for diabetic HbA1c testing.

The new connectivity package includes a proprietary connector interface box, cables, and a software upgrade. This enables EKF’s HbA1c analyzers to automatically transmit patient data to most Lab Information Management Systems (LIMS) or Hospital Information Systems (HIS). Using patient ID and increased demographic data (such as family name and date of birth) improves traceability and results recall speed. These can now be recorded by selecting from a pre-approved list or via the barcode scanner and keyboard.

Also, to ensure the integrity of results generated at the POC, security and QC are enhanced on Quo-Lab® and Quo-Test® through user ID and QC lockout functions, which are included in the connectivity package. By restricting access to trained users only, the lockout functions minimize the chances of user error and adhere to security protocols in many institutions. Furthermore, unauthorized users will be prevented from accessing patient information. Multiple user-defined QC lockout options are also available to POCT coordinators to enforce regular testing of QC materials and ensure compliance.

“HbA1c, or glycated haemoglobin, is well recognised as a reliable measure for glycemic control and managing patients with diabetes. As HbA1c levels reflect average circulating glucose concentration over two to three months, it can offer greater clinical information than a single glucose measurement,” said Gavin Jones, Diabetes Product Manager, EKF Diagnostics. “Our Quo-Lab® and Quo-Test® analyzers deliver lab-quality results for HbA1c from 4µL of blood within 4 minutes, enabling the consulting clinician to give immediate feedback to a patient. In addition to ensuring the reliability of results, our new connectivity package also allows the clinician to add commentary to any test result, further enhancing the monitoring and management of diabetes in a point-of-care setting.”

At Medica, EKF’s Stand C70, Hall 3, will feature live demonstrations of the new connectivity package for Quo-Lab® and Quo-Test® analyzers. In addition, other products from EKF’s in vitro diagnostics range for both point-of-care and central laboratory settings will be available to discuss and view. These include the Hemo Control, DiaSpect Tm, Biosen C-Line, and Lactate Scout+.